Bladder Cancer: More Questions Than Answers With pCR Endpoint

 
• By Derrick Gingery
Bladder-cancer-cells
Validating pCR as a surrogate endpoint could help advance drug development in muscle-invasive bladder cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D